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Objective: Study the impact of intra-articular interleukin-1 receptor antagonist (IL-1 ra) treatment
on lubricin biosynthesis following anterior cruciate ligament transection (ACLT) in the rat and evaluate
the effect of combined IL-1 ra and recombinant human lubricin (rhPRG4) treatments on chondrocyte
apoptosis.
Methods: ACLT was performed in male Lewis rats. Treatments included IL-1 ra or vehicle (n ¼ 36 in each
group). IL-1 ra intra-articular dosing was performed on days 1, 3, 5 and 7 following ACLT using Anakinra
(150 mg/ml; 40 ml). At 3 and 5 weeks, animals were sacriﬁced and RNAwas isolated. Histological analyses
included Safranin O and H&E. Lubricin synovial ﬂuid (SF) lavage concentrations were determined at 5
weeks. ACLT animals were treated with a single injection of vehicle, IL-1 ra (75 mg/ml; 40 ml), rhPRG4
(200 mg/ml; 40 ml), or IL-1 ra þ rhPRG4 (75 mg/ml þ 200 mg/ml; 40 ml) (n ¼ 6 in each group) on day 7
following ACLT and cartilage was probed for cleaved caspase-3 at 5 weeks.
Results: IL-1 ra treatment improved lubricin expression (P < 0.001) and lubricin SF lavage concentrations
in the IL-1 ra group was higher (P ¼ 0.005) than the vehicle. IL-1 ra treatment reduced cartilage and
synovial scores (P < 0.001) compared to vehicle. IL-1 ra and rhPRG4 acted synergistically to reduce
caspase-3 positive chondrocytes (P < 0.001) compared to individual treatments.
Conclusion: IL-1 ra treatment preserved lubricin following ACLT and a combined treatment of IL-1
ra þ rhPRG4 may act synergistically to reduce cartilage catabolism.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Lubricin/Proteoglycan 4 (PRG4) is a multifaceted glycoprotein,
secreted from the superﬁcial zone chondrocytes and synovium
with boundary lubricating and chondroprotective properties1e4.
Lubricin gene expression is down regulated by pro-inﬂammatory
cytokines e.g., interleukin-1 beta (IL-1 b) and tumor necrosis factor
alpha (TNF-a)5e9. Following an acute joint injury, lubricin synovial
ﬂuid (SF) concentrations are reduced10,11 and supplementation
with either puriﬁed human lubricin12e14, recombinant human: K.A. Elsaid, School of Phar-
MA 02115, USA.
said).
ternational. Published by Elsevier Llubricin (rhPRG4)15 or a truncated lubricin16 retards cartilage
degeneration in pre-clinical surgically induced osteoarthritis (OA)
models.
The objective of this study is to evaluate the impact of blocking
the effects of IL-1 on lubricin biosynthesis, lubricin SF levels and its
association with cartilage degeneration. We hypothesized that
antagonizing IL-1, following anterior cruciate ligament transection
(ACLT) in the rat, results in reversal of the down regulation of
lubricin expression, restoring lubricin levels in the SF. This effect is
associated with a reduction in chondrocyte apoptosis and the
severity of cartilage degeneration. Additionally, we have explored
the impact of simultaneously antagonizing IL-1 and supplementing
lubricin with intra-articular delivery of full-length rhPRG4 on
articular chondrocyte apoptosis, lubricin immunostaining in carti-
lage and matrix metalloproteinase-13 (MMP-13) cartilage distri-
bution in a rat ACLT model. Justiﬁcation for the second hypothesistd. All rights reserved.
K.A. Elsaid et al. / Osteoarthritis and Cartilage 23 (2015) 114e121 115comes from the fact that lubricin null (Prg4/) mice demonstrate
chondrocyte apoptosis in the absence of inﬂammation17.
Methods
ACLT in the rat
Transection of the ACL was performed in 9e10 weeks old male
Lewis rats (n ¼ 96). Following anesthesia with intraperitoneal Ke-
tamine and Dexmedetomidine, the right knee joint skin was
shaved, cleaned with povidone iodine topical antiseptic, and a
lateral skin incision was made along the patellar tendon to access
the joint capsule and expose the ACL. Severing the ACL was per-
formed using a # 11 surgical blade and a positive anterior draw
conﬁrmed ACLT. Closure of the joint capsule and animal skin was
performed using biodegradable PDSII sutures. In all animals, the
right knee joint was the ACL transected joint. All surgeries were
performed by KE and all required approvals were obtained from
MCPHS University IACUC committee. Control animals (n ¼ 5) were
age and sex-matched to the ACL transected animals and were used
for comparison.
Intra-articular administration of interleukin-1 receptor antagonist
(IL-1 ra), rhPRG4 or Phosphate Buffered Saline (PBS)
To evaluate the impact of IL-1 ra treatment on lubricin meta-
bolism following ACLT, ACL transected animals were injected with
40 ml of recombinant human IL-1 ra (supplied as 150 mg/ml Ana-
kinra, Amgen Inc, Thousand Oaks, CA) or PBS on days 1, 3, 5 and 7
following ACLT (n ¼ 36 in each group). Injections were performed
through the patellar tendon of the operated knee joint while the
animal is receiving inhalational isoﬂurane. At 3 and 5 weeks post
ACLT, animals were sacriﬁced and their joints were lavaged using
PBS followed by joint harvest (n ¼ 18 in each group at each time
point). The harvested joints were used for RNA extraction and
histological analyses as described below.
To study the impact of combining IL-1 ra and rhPRG4 on
chondrocyte apoptosis, ACL transected animals were injected with
a single 40 ml dose of either rhPRG4 (200 mg/ml quantiﬁed using
absorbance at 280 nm), 40 ml IL-1 ra (75mg/ml) or a combination of
rhPRG4 and IL-1 ra (40 ml) with a ﬁnal rhPRG4 and IL-1 ra con-
centrations of 200 mg/ml and 75 mg/ml, respectively. rhPRG4 is a
full-length product derived from Chinese Hamster Ovary (CHO)
cells (Lubris, Framingham, MA)18. Brieﬂy, the gene encoding the full
length 1404 amino acid human PRG4 was inserted into plasmid
vectors, commercially available at Selexis SA (Geneva, Switzerland),
for enhanced gene expression in mammalian cells. Speciﬁcally,
expression vectors encode the gene of interest under the control of
the human elongation factor-1-alpha (hEF-1-alpha) promoter
coupled to a CMV enhancer. Plasmids were veriﬁed by sequencing.
CHO-M cell lines derived from CHO-K1 cells (ATCC) adapted to
serum free cultivation conditions were used for the production of
rhPRG4. rhPRG4 richmediawas obtained from a shake ﬂask culture
with fed-batch cultivation (SFM4CHO medium, Hyclone) supple-
mented with 8 mM L-glutamine, hypoxanthine and thymidine (Life
Technologies). For this study, conditioned culture media were
subjected to ultraﬁltration/diaﬁltration (UFDF) followed by a three-
step chromatographic puriﬁcation process followed by ﬁnal UFDF
into PBS. Concentration was determined by inhibition enzyme-
linked immunosorbent assay (ELISA) using Mab 9G3 (EMDMilli-
pore) against known concentrations of rhPRG4 determined by dry
weight, and ﬁnal purity was determined to be 96% based on re-
sidual host cell protein concentrations (ELISA, Cygnus Technolo-
gies). The injectionwas performed on day 7 post ACLT (n¼ 6 in each
group) and these joints were harvested at 5 weeks following ACLT.Quantitative lubricin expression
Immediately following joint harvest, tibial plateau cartilage was
carefully dissected from the operated and contra-lateral knees and
was immediately snap-frozen and stored at 80C until RNA
isolation (n ¼ 9 in each group at each time point). Total RNA
isolation followed by quantitative lubricin expression was per-
formed as described previously in Ref. 12. Data was expressed as a
ratio of PRG4 expression in the operated knee to that in the
contralateral knee, standardized to GAPDH.
Lubricin quantitation in SF lavages and adjustment using urea
In a separate experiment, ACLT was performed on male Lewis
rats (n ¼ 16) as described above and animals were treated intra-
articularly with 40 ml of recombinant human IL-1 ra (150 mg/ml)
or PBS on days 1, 3, 5 and 7 following ACLT (n ¼ 8 in each group). A
total of six animals were used as controls. Lavaging of SF was per-
formed at week 5 following ACLTat the time of sacriﬁce by injecting
a total of 100 ml of PBS into the joint capsule followed by ﬂexing and
extending the joint for 10 times. We were successful in obtaining
lavages in six animals that had ACLT þ PBS, in six animals that had
ACLT þ IL-1 ra and six control animals. Additionally, sera were
collected at the time of sacriﬁce. Approximately 20e30 ml of ﬂuid
was recovered per animal. Lubricin SF lavage concentrations were
determined using an inhibition ELISA with lubricin-speciﬁc
monoclonal antibody 9G312. High-binding 96-well plate (Corning,
Sigma Aldrich) were coated with rhPRG4 at 5 mg/ml in PBS over-
night (100 ml per well). Subsequently, wells were blocked using 2%
bovine serum albumin (300 ml per well) for 2 h at room tempera-
ture. An 8-point standard curve of rhPRG4 with 100 mg/ml as the
highest concentration followed by two-fold dilutions or diluted SF
lavagesweremixedwithMab 9G3 (1:5000) in PBS and added to the
ELISA plate and incubated for 60 min at room temperature.
Following washing with PBSþ 0.1% tween 20, goat anti-mouse IgG-
HRP (ThermoScientiﬁc) at 1: 5000 dilution was added (100 ml per
well) and the plate was incubated for 60 min at room temperature.
Following washing with PBS þ 0.1% tween 20, one-step Turbo TMB
ELISA reagent (ThermoScientiﬁc) was added (100 ml per well) and
incubated for 15 min at room temperature. Subsequently, 2N sul-
furic acid was added (100 ml per well) and the absorbance was
measured at 450 nm. The lower detection limit of the assay was
approximately 1.5 mg/ml and the upper detection limit of the assay
was approximately 50 mg/ml. Using high molecular weight hyal-
uronic acid (2 mg/ml; R&D systems) as a diluent, the recovery of
rhPRG4 using this assay was calculated as 96.12 ± 5.69%.
Adjustment of lubricin lavage concentrations was performed
using the urea adjustment approach19,20. Urea concentrations were
determined in animal sera and SF lavages using a commercially
available kit (Abcam). The ratio of urea concentration in the serum
to that in the SF lavage was considered the dilution factor and was
multiplied by the SF lavage concentrations to arrive at the urea-
adjusted lavage concentrations.
Histological and immunohistochemical analyses
Parafﬁn-embedded coronal sections were taken from weight-
bearing areas of the articular cartilage of ACL transected joints of
each animal. Microtomed sections were collected approximately
every 250 mm to identify representative sections showing the
femoral condyles, tibial plateau and both menisci. Histological
stains included Safranin O/Fast green for histological scoring and
assessment of sulfated glycosaminoglycans (sGAGs) and hematox-
ylin and eosin (H&E) for synovitis scoring. Immunohistochemical
analyses included probing for lubricin using monoclonal antibody
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Fig. 1. Quantitative lubricin gene expression in articular cartilage, lubricin cartilage
immunostaining and SF lavage lubricin concentrations following ACLT and intra-
articular treatment with PBS or IL-1 ra at 3 and 5 weeks following ACLT. (A) Relative
lubricin cartilage expression in control and ACLT joints compared to contra-alteral
joints and normalized to glyceraldehyde-3-phosphare dehydrogenase (GAPDH) and
received intra-articular injections of PBS or IL-1 ra. Individual data points are presented
and the median value is highlighted with an “X”. *Indicates that lubricin cartilage
expression in control joints was signiﬁcantly higher compared to 3-week and 5-week
ACLT treated with PBS or IL-1 ra (P < 0.001). **Indicates that lubricin cartilage
expression in 3 week ACLT joints treated with IL-1 ra was signiﬁcantly higher
compared with 3 and 5 week ACLT joints treated with PBS (P ¼ 0.002), (P ¼ 0.001).
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1:200 dilution and MMP-13 antibody (Abcam) at 1:200 dilution
followed by developing using Vectastain ABC kit (Vector
Laboratories).
Histological scoring and semi-quantitative histological analysis
A total of four histological sections were stained with Safranin
O/FG for assessment of cartilage integrity and four adjacent histo-
logical sections were stained with H&E for synovitis scoring.
Cartilage scoring was performed using the OA Research Society
International (OARSI) modiﬁed Mankin scoring except for osteo-
phyte formation21. Scoring was performed on themedial and lateral
joint compartments of the harvested knees and an overall average
was reported. Synovial histopathology scoring was performed us-
ing the criteria reported previously in Ref. 22 and included exam-
ination of intimal hyperplasia, inﬂammatory cell inﬁltration,
subintimal ﬁbrosis and vascularity with scores ranging from 0 to 3
for each criterion and a range of aggregate scores between 0 and 12.
Quantitative estimation of caspase-3 positive chondrocytes was
performed using four histological specimens per animal and the
number of caspase-3 positive chondrocytes was determined in the
medial and lateral compartments of the tibial plateau and
expressed as a percentage of total chondrocytes visualized using
adjacent sections stained with H&E.
Determination of urinary CTXII (uCTXII) levels in controls, PBS and
IL-1 ra-treated ACLT animals
On day 34 following ACLT of animals receiving PBS or IL-1 ra,
animals were housed in metabolic cages and 24-h urine collection
was performed. Urine samples were centrifuged at 3000 rpm for
20 min and stored at 20C. The urinary concentration of CTXII
neoepitopes was determined using the preclinical Urine Cartilaps
ELISA (Immunodiagnostics Systems). Urinary creatinine was
determined using the Creatinine Assay Kit (Abcam) and the uCTXII
concentrations were expressed as pg per mg creatinine per 24 h.
Statistical analyses
Variables in the relative lubricin expression, lubricin SF lavage
concentrations, uCTXII levels, modiﬁed Mankin and synovial his-
tology scores, and percentage of caspase-3 positive cells analyses
were initially examined for equal variance and normality. Variables
that satisﬁed both assumptions were analyzed using one-way
analysis of variance (ANOVA) followed by post-hoc Tukey's test
for pairwise comparisons. Variables that failed any of these two
assumptions were analyzed using ANOVA on the ranks with
Tukey's test for pairwise comparisons. Statistical signiﬁcance was
set at a¼ 0.05 a priori. All statistical analyses were performed using
Sigma Plot (version 11.0). Data are graphically presented as scatter***Indicates that lubricin cartilage expression in 5 week ACLT joints treated with IL-1 ra
was signiﬁcantly higher compared with 5 week ACLT joints treated with PBS
(P ¼ 0.001). (B) mAb 9G3 immunostaining for lubricin from (A) control, (B) 3-week
ACLT joints treated with PBS, (C) 3-week ACLT joints treated with IL-1 ra, (D)
5-week ACLT joints treated with PBS, and (E) 5-week ACLT joints treated with IL-1 ra.
Arrows point to intense lubricin staining on the surface of articular cartilage and in
superﬁcial zone chondrocytes compared to 3 and 5 week ACLT joints treated with PBS.
Scale ¼ 50 mm. (C) Urea-adjusted lubricin SF lavage concentrations in control, 5-week
ACLT animals following treatment with PBS or IL-1 ra (n ¼ 6 in each group). Individual
data points are presented and the median value is highlighted with an “X”. *Indicates
that lubricin SF lavage concentrations in control animals were signiﬁcantly higher
compared with 5-week ACLT joints treated with PBS (P < 0.001). **Indicates that
lubricin SF lavage concentrations in 5-week ACLT animals treated with IL-1 ra was
signiﬁcantly higher compared with 5-week ACLT animals treated with PBS (P ¼ 0.005).
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Fig. 2. Impact of IL-1 ra treatment on cartilage and synovial histopathologies and
uCTXII release following ACLT in the rat. (A) Representative Safranin-O (top panel)
stained cartilage and H&E (bottom panel) stained synovium from control animals and
animals that underwent ACLT followed by intra-articular injection of PBS on days 1, 3, 5
and 7 (PBS) or IL-1 ra (IL-1 ra). The arrow points to synovial thickening and inﬁltration
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caspase-3 positive chondrocytes across different experimental
groups are reported in the text using the mean along with 95%
conﬁdence interval (CI).
Results
Impact of IL-1 ra treatment on lubricin metabolism following ACLT
The impact of IL-1 ra treatment on PRG4 gene expression, SF
lavage concentrations and cartilage surface deposition is presented
in Fig. 1. At 3 and 5 weeks following ACLT, lubricin gene expression
was signiﬁcantly reduced following PBS or IL-1 ra treatments
compared to control animals (P < 0.001) [Fig. 1(A)]. At 3 weeks
following ACLT, PRG4 gene expression in joints receiving IL-1 ra
treatment was signiﬁcantly higher compared with PBS treatment
(P ¼ 0.002). Similarly, lubricin gene expression in joints receiving
IL-1 ra at 5 weeks post-ACLT was signiﬁcantly higher than lubricin
expression in joints receiving PBS (P ¼ 0.001). There was no sig-
niﬁcant difference in lubricin expression between joints receiving
IL-1 ra treatments at 3 and 5 weeks post-ACLT (P ¼ 0.383).
Representative cartilage sections immunoprobed for lubricin is
presented in Fig. 1(B). Control cartilage displayed intense staining
for lubricin on the surface of articular cartilage as well as wide-
spread distribution in the superﬁcial zone chondrocytes and less
prevalence in the middle zone. At 3 and 5 weeks post-ACLT, PBS-
treated joints displayed a progressive loss of surface deposition of
lubricin and lack of lubricin staining in the superﬁcial zone chon-
drocytes. On the contrary, IL-1 ra treatment appeared to preserve
lubricin surface staining and superﬁcial zone chondrocyte expres-
sion. Urea-adjusted lubricin SF lavage concentrations are presented
in Fig. 1(C). Lubricin SF lavage concentrations in control animals
were signiﬁcantly higher (P < 0.001) than 5-week ACLT animals
treated with PBS. Additionally, SF lavage concentrations in ACLT
animals treated with IL-1 ra were signiﬁcantly higher (P ¼ 0.005)
compared with ACLT animals treated with PBS. There was no sig-
niﬁcant difference in lubricin SF lavage concentrations between
control animals and ACLT animals treated with IL-1 ra.
Impact of IL-1 ra treatment on cartilage and synovial histopathology
and uCTXII release following ACLT
The disease-modulating effect of IL-1 ra treatment is presented
in Fig. 2. Representative cartilage and synovium sections from
control animals and from ACLT animals receiving PBS or IL-1 ra are
presented in Fig. 2(A) and (B). ACLT animals receiving PBS displayed
loss of superﬁcial zone cartilage, surface ﬁbrillation and loss of
sGAG staining. Similarly, PBS-treated ACL transected joints exhibi-
ted synovial hyperplasia and inﬁltration of inﬂammatory cells. IL-1
ra treatment preserved the articular cartilage integrity and sGAGof inﬂammatory cells in the PBS-treated group. Scale ¼ 50 mm. (B) Modiﬁed OARSI
scores of control (n ¼ 5), PBS-treated ACLT animals (n ¼ 9) and IL-1 ra-treated ACLT
animals (n ¼ 9). Individual data points are presented and the median value is high-
lighted with an “X”. *Indicates that OARSI scores of the PBS group were signiﬁcantly
higher than OARSI scores of control or the IL-1 ra groups (P < 0.001). (C) Synovial
histopathology scores of control (n ¼ 5), PBS-treated ACLT animals (n ¼ 9) and IL-1 ra-
treated ACLT animals (n ¼ 9). Individual data points are presented and the median
value is highlighted with an “X”. *Indicates that synovial histopathology scores of PBS-
treated ACLT animals were signiﬁcantly higher than control and IL-1 ra-treated ACLT
animals (P < 0.001). **Indicates that synovial histopathology scores of IL-1 ra-treated
ACLT animals were signiﬁcantly higher than control animals (P < 0.001). (D)
uCTXII levels, adjusted to urinary creatinine in urines collected over a 24 h period in
control animals (n ¼ 5) or at 5 weeks post-ACLT treatment with PBS (n ¼ 10) or IL-1 ra
(n ¼ 13). Individual data points are presented and the median value is highlighted with
an “X”. *Indicates that uCTXII levels in PBS-treated ACLT animals were signiﬁcantly
higher than uCTXII levels in control or IL-1 ra treated ACLT animals (P < 0.001).
Fig. 3. Impact of treatment with rhPRG4 and IL-1 ra alone and in combination on
chondrocyte apoptosis, lubricin and MMP-13 immunostaining following ACLT and a
single intra-articular treatment with IL-1 ra (75 mg/ml; 40 ml), rhPRG4 (200 mg/ml;
40 ml) or IL-1 ra þ rhPRG4 (75 mg/mle200 mg/ml; 40 ml). (A) Representative cleaved
caspase-3 (top panel), lubricin (middle panel) and MMP-13 (bottom panel) immuno-
stained articular cartilage from controls and animals that underwent ACLT followed by
intra-articular treatment with PBS (PBS), IL-1 ra (IL-1 ra), recombinant lubricin
(rhPRG4) and a combination of IL-1 ra and rhPRG4 (IL-1 ra þ LUB). Scale ¼ 50 mm. (B)
Semi-quantitative analysis of percentage of cleaved caspase-3 positive chondrocytes in
controls (n ¼ 5) and ACLT animals treated with PBS, IL-1 ra, rhPRG4 or IL-1 ra þ rhPRG4
(n ¼ 6 in each group). Individual data points are presented and the median value is
highlighted with an “X”. *Indicates that percentage caspase-3 positive cells in the PBS-
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inﬁltration.
PBS-treated ACL transected joints had signiﬁcantly higher OARSI
Mankin scores compared to controls and IL-1 ra treated ACL
transected joints [Fig. 2(B)]. There was no signiﬁcant difference
between OARSI scores in controls and IL-1 ra treated ACLT joints
(P ¼ 0.383). PBS-treated ACLT joints had signiﬁcantly higher sy-
novial pathology scores compared with controls and IL-1 ra-treated
joints (P < 0.001) [Fig. 2(C)]. Synovial histopathology scores in IL-1
ra-treated ACL transected joints were signiﬁcantly higher
compared with controls (P < 0.001). The uCTXII levels from PBS-
treated ACL transected joints were signiﬁcantly higher than con-
trols or IL-1 ra treated ACLT joints (P < 0.001) [Fig. 2(D)]. There was
no signiﬁcant difference in uCTXII release between controls and IL-
1 ra-treated ACL transected joints.
Impact of recombinant lubricin (rhPRG4) and IL-1 ra treatments on
chondrocyte apoptosis, lubricin and MMP-13 immunostaining
following ACLT
Representative cartilage sections probed for cleaved caspase-3,
lubricin and MMP-13 are presented in Fig. 3(A). Control joints
lacked cleaved caspase-3 and MMP-13 staining and displayed
lubricin deposition on the surface of articular cartilage and wide-
spread presence in and around superﬁcial zone chondrocytes. In
PBS-treated ACL transected joints, cartilage exhibited intense
cleaved caspase-3 and MMP-13 staining with lack of cartilage
lubricin staining. IL-1 ra and rhPRG4 treatments re-established
lubricin immunostaining in the superﬁcial layer of articular carti-
lage and qualitatively further reduced cleaved caspase-3 and MMP-
13 staining. Compared to PBS-treated ACL transected joints, ani-
mals receiving IL-1 raþ lubricin had reduced cleaved caspase-3 and
MMP-13 staining.
The mean percentage of caspase-3 chondrocytes in control
joints was 9.7, 95% CI (4.7e14.7) compared to ACL transected joints
receiving PBS 76.2, 95% CI (62.6e89.9), IL-1 ra 51.8, 95% CI
(40.4e63.2), rhPRG4 50.0, 95% CI (41.2e58.7) and 34.0, 95% CI
(22.0e46.0) in the IL-1 ra þ rhPRG4 treatment group. The per-
centage of chondrocytes positive for caspase-3 positive in the PBS-
treated animals was signiﬁcantly higher than in controls
(P < 0.001), IL-1 ra (P ¼ 0.003), rhPRG4 (P ¼ 0.001) and IL-1
ra þ rhPRG4 treated groups (P < 0.001) [Fig. 3(B)]. The percent-
age of caspase-3 positive chondrcocytes in the IL-1 ra-treated ani-
mals was signiﬁcantly higher than percentage of caspase-3 positive
chondrcocytes in controls (P < 0.001) and the IL-1 ra þ rhPRG4
treated group (P ¼ 0.039).
Discussion
ACL injury is a signiﬁcant risk factor for the development of
posttraumatic OA (PTOA)23e26, with current treatment modalities
continuing to provide suboptimal outcomes27e29. In the acute
phase following a joint injury, pro-inﬂammatory cytokines e.g., IL-1,
TNF-a and IL-6 were shown to be elevated in the SF predisposing
articular cartilage to cytokine-mediated degradation30e32. Blocking
the effects of these key pro-inﬂammatory cytokines may prove
useful in retarding the onset of cartilage degeneration and eventual
PTOA. In this study, early high-dose treatment with IL-1 ra wastreated animals was signiﬁcantly higher than percentage caspase-3 positive cells in
controls (P < 0.001), IL-1 ra (P ¼ 0.003), rhPRG4 (P ¼ 0.001) and IL-1 ra þ rhPRG4
(P < 0.001). **Indicates that percentage caspase-3 positive cells in the IL-1 ra-treated
animals was signiﬁcantly higher than percentage caspase-3 positive cells in controls
(P < 0.001) and IL-1 ra þ rhPRG4 (P ¼ 0.039).
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lubricin in a time-dependent manner. The protective effect of IL-1
ra on lubricin was evidenced by an observed recovery in lubricin
expression as early as 2-weeks following the conclusion of drug
dosing coupled with an increase in lubricin SF lavage concentra-
tions at 5 weeks post ACLT. Lubricin expression levels were not fully
restored to control values with IL-1 ra treatment. This partial effect
can be rationalized by the fact that lubricin is also down regulated
by TNF-a, that is also up regulated in this model9. The reported
lubricin SF lavage concentrations in this work are signiﬁcantly
higher than earlier reports9,12 due to the urea adjustment effect,
which we did not employ previously. Additionally, the reported
urea-adjusted SF lavage lubricin concentrations in control rats were
higher than what has been reported for lubricin concentrations in
the SF from contralateral uninjured joints of patients with a uni-
lateral ACL injury11. This may be attributed to inter-species vari-
ability, the use of different detection antibodies in the ELISA assays
as well as the use of rhPRG4 as a standard in this study as opposed
to the use of puriﬁed human lubricin in the earlier report11.
Furthermore, lavaging the knee joint may artiﬁcially elevate SF
lubricin concentration by solubilizing cartilage and synovium-
bound lubricin. Interestingly, urea adjustment did not alter
observed differences among the different experimental groups. For
the unadjusted SF lavage concentrations, control levels were higher
than ACLT animals that received PBS, while IL-1 ra treatment
increased lubricin SF lavage concentration compared to PBS.
Concomitant with restoration of lubricin expression was a
reduction in the extent of cartilage degeneration, reﬂected by a
lowering of OARSI scores, a reduction in the extent of synovial hy-
perplasia and inﬂammation and in uCTXII levels. A reduction in
synovial inﬂammation is an important disease-modifying effect as
chronic synovial inﬂammation contributes to sustained cartilage
degradation. Even with a lowering of IL-1 ra dosing and reduced
dosing frequency, important disease-modifying effects were still
observed. Most signiﬁcantly, a single dose of IL-1 ra resulted in
preserving superﬁcial and middle zone chondrocytes' ability to
synthesize lubricin and reduced the number of chondrocytes un-
dergoing apoptosis. Chondrocyte apoptosis is a key contributor to
cartilage degeneration following an acute joint injury and inhibi-
tion of apoptosis was shown to be efﬁcacious in reducing the extent
of OA in a surgically induced OA animal model33,34. IL-1 b activates
the nuclear factor kappaB (NFkB) signaling pathway with down-
stream effects of promoting inﬂammation, increase expression of
proteolytic enzymes e.g., MMP-13, and activation of effector cas-
pases e.g., caspase-335e37. The reduction in caspase-3 activation,
shown with IL-1 ra treatment is due to the prevention of IL-1b
binding to the IL-1 receptor and down-stream activation of the NF-
kappa B pathway.Whilewe have observed a signiﬁcant reduction in
the percentage of articular chondrocytes with activated caspases-3,
wewere not able to observe any difference in the extent of MMP-13
staining between PBS and IL-1 ra treatment. Our ﬁndings support
the disease-modifying effects of intra-articular IL-1 ra treatment
and conﬁrm previous ﬁndings that IL-1 ra treatment is beneﬁcial in
retarding cartilage damage in PTOA animal models38,39.
A single-dose rhPRG4 treatment also signiﬁcantly reduced the
activation of caspase-3 in articular chondrocytes, as demonstrated
by a reduction in percentage of caspases-3 positive chondrocytes.
The ability of native human lubricin to reduce caspases-3 activation
in chondrocytes has been previously documented in an inﬂam-
matory PTOA animal model12. Puriﬁed human synoviocyte lubricin
also prevented caspases-3 activation ex vivo when used as a
lubricant between two bovine cartilage explants compared to
either using PBS or a lubricin-deﬁcient SF17. Additionally, lubricin
null (Prg4/) mice displayed increased caspases-3 activation in
articular cartilage compared to age-matched heterozygous or wildtype animals which express Prg4. The majority of the caspases-3
positive chondrocytes were located in the superﬁcial and upper
middle zone17. While the median percentage of caspase-3 positive
cells in cartilage of ACL transected joints was 79%, the median in
rhPRG4-treated animals was 49%, reﬂecting a 38% reduction in
caspase-3 positive chondrocytes. Interestingly, the abundance of
cells that lacked caspase-3 staining with rhPRG4 treatment was in
the superﬁcial andmiddle zones of articular cartilage. In addition to
preserving chondrocytes' ability to synthesize lubricin, rhPRG4
treatment has reduced the extent of MMP-13 staining in articular
cartilage compared to PBS-treated animals.
The PTOA disease process is complex to the extent that a
treatment with a single mechanism of action may not confer the
optimal chondroprotective effect to reduce the progression of
cartilage degeneration40. The use of combined treatment modal-
ities with different mechanisms of action may exert a synergistic
effect leading to a better control of the PTOA disease progression. Il-
1 ra and lubricin exert their chondroprotective effect via different
mechanisms and have individually shown promise as anti-PTOA
treatments. We aimed to explore the impact of combining the
two treatments on chondrocyte apoptosis, MMP-13 and lubricin
expression in articular cartilage following ACLT. The combination of
IL-1 ra and rhPRG4 has resulted in a synergistic effect on caspase-3
activation in chondrocytes, with the median percentage caspase-3
positive chondrocytes following IL-1 ra þ rhPRG4 treatment of 34%
compared to a median of 52% and 49% following IL-1 ra and rhPRG4
treatments, respectively. This represents a 57% reduction in per-
centage of caspase-3 positive chondrocytes compared to a 34% and
38% reduction following PBS and IL-1 ra treatments. Similarly, IL-1
ra þ rhPRG4 treatment has reduced MMP-13 staining in articular
cartilage to a greater extent compared to either IL-1 ra or rhPRG4
treatments. Taken together, these effects may demonstrate the
beneﬁt of combining a biological response modifying agent
(Anakrina) with a tribosupplement (rhPRG4) which employ
different therapeutic mechanisms. The full anabolic potential of
this approach has not been maximized since the relative timing of
the administration of both biologics may be important in lieu of co-
administration.
In conclusion, our study has evaluated the impact of blocking
the effects of IL-1 on lubricin metabolism and biosynthesis
following a traumatic joint injury in the rat. IL-1 ra antagonized the
IL-1 mediated reduction in lubricin expression and this effect
occurred at an earlier stage prior to any appreciable cartilage
damage. Individually, IL-1 ra and rhPRG4 intra-articular treatments
reduced chondrocyte apoptosis following ACLT in the rat.
Combining IL-1 ra and rhPRG4 resulted in a synergistic anti-
apoptotic effect and may provide a potential therapeutic strategy
to treat PTOA.
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